
Monday, February 12, 2018 2:00:15 PM
Didn't you pump the whole ICC Trial as the make or break for DCTH? Company stated they expected to begin in March this year...now it should become reality!
USE OF PROCEEDS
Based on a public offering price of $0.02 per share, we expect to receive net proceeds from the sale of the securities that we are offering to be approximately $4.4 million, after deduction of placement agent fees, and commissions and estimated expenses payable by us.
We intend to use the net proceeds from this offering (including any resulting from the exercise of the warrants, if any) for:
• the clinical and regulatory development of clinical studies, including the Phase 3 Ocular Melanoma liver metastases trial, a registration trial for intrahepatic cholangiocarcinoma, investigator initiated trials mCRC and pancreatic cancer metastatic to the liver, and European Union Commercial Registry;
• commercialization of our products,
• obtaining regulatory approvals;
• research;
• capital expenditures and development of joint ventures and licensing arrangements for our products;
• working capital; and
• the balance, if any, for other general corporate purposes.
This states the money will be to start the Phase 3 ICC Trial...of course with the SPA they already have with the FDA regarding design, timelines, number of required patients, etc...
Also states mCRC trials? Pancreatic cancers, and European commercializations?
Doesn't look that bad buddy!
IMHO
In My Own Personal Opinion Of Course!

Liked By
Spread the love. Be the first to like this post!
Recent DCTH News
- Small Company Offering and Sale of Securities Without Registration (d) • Edgar (US Regulatory) • 03/31/2023 03:32:01 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 03/30/2023 01:00:54 PM
- Delcath Systems Announces Closing of Private Placement of up to $85 Million • PR Newswire (US) • 03/30/2023 01:41:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/28/2023 10:04:20 AM
- Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update • PR Newswire (US) • 03/27/2023 12:20:00 PM
- Delcath Systems Announces up to $85 Million Financing • PR Newswire (US) • 03/27/2023 12:15:00 PM
- Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023 • PR Newswire (US) • 03/27/2023 12:10:00 PM
- Annual Report (10-k) • Edgar (US Regulatory) • 03/27/2023 12:00:48 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 02/27/2023 10:00:16 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/24/2023 11:08:32 AM
- Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch • PR Newswire (US) • 02/16/2023 01:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/14/2023 03:59:47 PM
- Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit • PR Newswire (US) • 02/14/2023 01:49:00 PM
- Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16 • PR Newswire (US) • 01/30/2023 01:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/23/2023 12:01:47 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 01/23/2023 11:04:04 AM
- Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology • PR Newswire (US) • 01/17/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/10/2023 09:13:57 PM
- Securities Registration Statement (simplified Form) (s-3) • Edgar (US Regulatory) • 01/10/2023 09:08:24 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 12/29/2022 10:28:09 PM
- Tender Offer Statement by Issuer (sc To-i) • Edgar (US Regulatory) • 12/21/2022 05:18:41 PM
- Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 12/16/2022 10:07:45 PM
- Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4) • PR Newswire (US) • 12/16/2022 09:15:00 PM
- Small Company Offering and Sale of Securities Without Registration (d) • Edgar (US Regulatory) • 12/16/2022 08:04:28 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 02:32:48 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM